Prior Use of GLP-1 Receptor Agonists versus SGLT2 Inhibitors and Clinical Outcomes After Sepsis in Patients with Type 2 Diabetes: A Propensity Score-Matched Cohort Study.
People with diabetes taking GLP-1 drugs before developing sepsis had lower 90-day mortality than those on other medications, suggesting protective benefits.
We compared clinical outcomes among patients with type 2 diabetes (T2D) who developed sepsis according to prior GLP-1 receptor agonists (GLP-1RAs) or SGLT2 inhibitors (SGLT2is) use. Among propensity-matched patients with type 2 diabetes who developed sepsis, prior GLP-1 receptor agonist use was associated with lower 90-day mortality and selected cardiovascular and renal risks than prior SGLT2 inhibitor use, although residual confounding remains possible.
What the study was
- Study design
- Propensity score-matched retrospective cohort study
- Population
- Human study population described in the abstract
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Drug design, development and therapy
Why it surfaced
Matched Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; Propensity score-matched retrospective cohort study; human evidence; conservative score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.